Extended induction treatment with open-label intravenous risankizumab was effective in increasing clinical response and remission rates at week 26 in patients with moderate to severe Crohn’s disease. Open-label subcutaneous risankizumab maintained remission until week 52 in most patients who were in clinical remission at week 26, according to data from an extended phase 2 trial published online July 25, 2018 in The Lancet Gastroenterology & Hepatology.